<DOC>
	<DOCNO>NCT00804830</DOCNO>
	<brief_summary>Anaplastic Thyroid Cancer aggressive disease . The investigator believe angiogenesis important tumor progress . Preclinical data suggesting . This prospectively want treat patient avastin ( doxorubicin ) . However , local control major concern . Therefore , patient initially treat hyperfractionated radiotherapy undergo surgery . Then enter study .</brief_summary>
	<brief_title>Avastin Doxorubicin Postoperatively Patients With Anaplastic Thyroid Cancer</brief_title>
	<detailed_description>Patients Anaplastic Thyroid Cancer poor prognosis . We treat patient initially standard radiochemotherapy , consist doxorubicin 20mg fixed dose/week hyperfractionated radiotherapy 1,6 Gy twice daily 46 Gy total . The first week radiotherapy , also receive Avastin 15mg/kg . 1-2 week radiotherapy patient undergo surgery primary tumor . After `` standard '' therapy patient include study . Treatment 20 mg fix dose doxorubicin q1w avastin 15mg/kg q3w . Treatment continue maximum 6 month progress intolerable side effect occur .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Thyroid Carcinoma , Anaplastic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>cytologically histologically verify anaplastic thyroid cancer complete standard therapy operate R0 R1 surgery Performance Status 02 ( pulmonary mets PS 01 ) normal wound heal neutrophil &gt; 1,5 million/ml platelet &gt; 100 million/ml bilirubin &lt; 2 ULN creatinin &lt; 150mikromol/L PS 34 ( pulmonary mets 24 ) R2 resection primary tumor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>adjuvant</keyword>
	<keyword>Anaplastic thyroid cancer</keyword>
</DOC>